Valneva and CSL Seqirus Partner to Boost Vaccine Distribution in Germany

In a significant move for the specialty vaccine market, Valneva SE has inked a deal with CSL Seqirus. This agreement centers on the marketing and distribution of several proprietary vaccines within Germany, promising a streamlined approach in Europe’s travel vaccine sector.

Strategic Alliance for Vaccine Sales

Valneva SE, a specialized vaccine company, disclosed an exclusive agreement with CSL Seqirus. Starting July 2025, CSL Seqirus will begin commercializing Valneva’s chikungunya vaccine, IXCHIQ^®. This partnership also includes the Japanese Encephalitis vaccine, IXIARO^®, and the cholera/ETEC vaccine, DUKORAL^®, from January 2026.

This new collaboration replaces the previous agreement Valneva had with Bavarian Nordic, set to expire at the close of December 2025. The new partnership is slated for a three-year duration and includes purchase volume stipulations, along with standard termination clauses for control changes and non-performance.

“We are excited to join forces with CSL Seqirus to continue developing our commercial sales in Germany. CSL’s strong commercial presence in Germany will ensure seamless distribution of our vaccines in Europe’s largest travel vaccine market, which nicely complements our in-house commercial infrastructure focused on other key markets in Europe.”

—Dipal Patel, Chief Commercial Officer at Valneva

Travel vaccination rates are on the rise, with approximately 60% of travelers seeking pre-travel health advice, highlighting the importance of efficient vaccine distribution (Statista, 2024).

Financial and Future Outlook

Valneva’s product sales hit €48.6 million in the first quarter of 2025, with proprietary vaccines accounting for €42.8 million. The company projects a sales increase to €170-180 million in 2025, which is expected to drive positive cash flow for its overall commercial activities.

As a specialty vaccine firm, Valneva is focused on developing and marketing prophylactic vaccines for infectious diseases. Their approach involves expertise in multiple vaccine modalities, aiming to offer first-in-class solutions. This includes their Lyme disease vaccine candidate, which is in advanced clinical development in partnership with Pfizer, along with vaccines for Shigella and the Zika virus.

This partnership signifies Valneva’s strategic expansion in the German market, with a focus on long-term growth and continued innovation in the vaccine sector. The agreement with CSL Seqirus is expected to strengthen Valneva’s market presence and support the advancement of its vaccine pipeline.